Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Immunic, Inc. develops novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), focused on multiple sclerosis. Company news commonly covers clinical and scientific presentations, patent protection for vidofludimus calcium, pipeline updates, and corporate communications tied to its late-stage development strategy.
Updates also include governance changes, board and executive appointments, Nasdaq listing compliance, capital actions such as its reverse stock split, and investor conference participation. Immunic's pipeline references additional earlier-stage programs, including IMU-856 and IMU-381, tied to neurodegenerative, chronic inflammatory, and autoimmune-related disease areas.
Immunic, Inc. (Nasdaq: IMUX) announced the enrollment of the first patients in the IONIC trial, a phase 2b clinical study for its oral DHODH inhibitor, IMU-838, targeting COVID-19. The trial aims to assess the efficacy and safety of IMU-838 combined with Oseltamivir in 120 adults with moderate-to-severe cases. IMU-838 has shown promising preclinical activity against SARS-CoV-2 and a favorable safety profile in earlier trials. The study is supported by the UHCW NHS Trust and LifeArc's £10 million initiative to expedite COVID-19 therapeutics.
Immunic, Inc. (Nasdaq: IMUX) announced its inclusion in the Russell 3000 Index effective June 29, 2020, following the annual reconstitution. This milestone reflects Immunic's progress in developing oral therapies for chronic inflammatory and autoimmune diseases, particularly its lead compound, IMU-838, which is undergoing four Phase 2 trials. Inclusion in the Russell 3000 Index enhances visibility and liquidity for the company's stock, with approximately $9 trillion in assets benchmarked against Russell indexes.
Immunic, Inc. (Nasdaq: IMUX) has begun dosing the first patients in its phase 2 CALVID-1 clinical trial for IMU-838, a selective oral DHODH inhibitor, aimed at treating moderate COVID-19. The trial, approved by regulatory bodies in Germany, the U.S., and other European countries, includes 230 hospitalized patients across 10 to 35 centers. Top-line data is expected later this year, with an interim analysis planned after 200 patients. IMU-838 has strong preclinical support and aims to show efficacy, safety, and tolerability, potentially leading to a phase 3 trial depending on interim results.